<DOC>
	<DOCNO>NCT02864758</DOCNO>
	<brief_summary>The purpose study compare one-year two-year risk follow individual outcome : Stroke systemic embolism ( SE ) , major bleed death new user anticoagulant Stroke prevention atrial fibrillation ( SPAF ) drug exposure : rivaroxaban versus Vitamin K antagonist ( VKA ) , rivaroxaban versus dabigatran</brief_summary>
	<brief_title>Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban Atrial Fibrillation France</brief_title>
	<detailed_description>Main objective : To compare one-year two-year risk follow individual outcome : Stroke systemic embolism ( SE ) , major bleed death new user anticoagulant SPAF drug exposure : rivaroxaban versus VKA , rivaroxaban versus dabigatran . Secondary objective : - To describe drug exposure rivaroxaban , dabigatran , VKA SPAF new user , well pattern use ; - To compare one-year two-year risk follow individual outcome : composite stroke SE , major bleed death , clinically relevant bleeding ( CRB ) acute coronary syndrome ( ACS ) new user anticoagulant SPAF drug exposure : rivaroxaban versus VKA , rivaroxaban versus dabigatran ; - To estimate cumulative incidence incidence rate individual main secondary outcome ( stroke SE , major bleeding , CRB , death , composite criterion , ACS ) , well accord individual diagnose outcome , drug exposure rivaroxaban , dabigatran , VKA ; - To estimate cumulative incidence individual main secondary outcome ( stroke SE , major bleeding , CRB , death , composite criterion , ACS ) , well accord individual diagnose outcome post-anticoagulant exposure rivaroxaban , dabigatran , VKA ( i.e . anticoagulant discontinuation ) ; - To assess outcome risk factor , include ( limited ) , gender , age , stroke bleed risk score ( CHA2DS2-VASc HAS-BLED ) , low high dosage index date DOAC , drug predispose bleed drug exposure significant baseline characteristic ; - To describe compare healthcare resource utilisation relate SPAF rivaroxaban , dabigatran , VKA exposure , include outcome , related cost societal perspective French healthcare insurance perspective .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Definite nonvalvular atrial fibrillation : A first reimburse dispensation rivaroxaban , dabigatran , VKA 2013 2014 , No previous DOAC ( rivaroxaban , dabigatran , apixaban ) VKA dispensation previous three year , Definite AF information database Probable nonvalvular atrial fibrillation : A first reimburse dispensation rivaroxaban , dabigatran , VKA 2013 2014 , No previous DOAC ( rivaroxaban , dabigatran , apixaban ) VKA dispensation previous three year , Probable AF information database ( use development AF disease score , see variable definition ) , Patients Rheumatic valve disease Patients valve replacement Patients treat anticoagulant venous thromboemboslim prevention venous thromboembolism orthopedic surgery</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>